Geron (NASDAQ:GERN) Receives Buy Rating from HC Wainwright

Geron (NASDAQ:GERN)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $9.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 126.13% from the stock’s previous close.

Other analysts have also recently issued research reports about the company. Leerink Partnrs raised Geron to a “strong-buy” rating in a research report on Monday, September 9th. Scotiabank initiated coverage on shares of Geron in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 price target on the stock. Leerink Partners initiated coverage on shares of Geron in a research report on Monday, September 9th. They set an “outperform” rating and a $7.00 price target for the company. Finally, Barclays raised shares of Geron to a “strong-buy” rating in a report on Friday, November 29th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $7.15.

Geron Stock Up 1.3 %

Geron stock opened at $3.98 on Tuesday. The business has a fifty day moving average price of $4.10 and a 200-day moving average price of $4.34. Geron has a 1-year low of $1.64 and a 1-year high of $5.34. The stock has a market capitalization of $2.41 billion, a price-to-earnings ratio of -12.44 and a beta of 0.51. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74.

Geron (NASDAQ:GERN) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.05. The firm had revenue of $28.27 million during the quarter, compared to analyst estimates of $18.97 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. Geron’s revenue was up 17138.4% on a year-over-year basis. During the same period last year, the firm posted ($0.08) EPS. Equities research analysts forecast that Geron will post -0.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Geron

Large investors have recently made changes to their positions in the stock. National Bank of Canada FI lifted its stake in Geron by 1,200.0% during the second quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 6,000 shares in the last quarter. Readystate Asset Management LP acquired a new position in Geron during the 3rd quarter worth about $58,000. Rovin Capital UT ADV purchased a new position in Geron during the 3rd quarter valued at about $62,000. Empowered Funds LLC purchased a new position in Geron during the 3rd quarter valued at about $67,000. Finally, Inspire Advisors LLC acquired a new position in Geron in the 3rd quarter valued at about $68,000. 73.71% of the stock is currently owned by institutional investors and hedge funds.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.